S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:BTTX

Better Therapeutics (BTTX) Stock Price, News & Analysis

$0.01
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.0127
$0.0160
50-Day Range
$0.01
$0.22
52-Week Range
$0.01
$1.61
Volume
899,375 shs
Average Volume
6.79 million shs
Market Capitalization
$698,040.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Better Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
42,757.1% Upside
$6.00 Price Target
Short Interest
Bearish
8.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Better Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.86) to ($0.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.04 out of 5 stars

BTTX stock logo

About Better Therapeutics Stock (NASDAQ:BTTX)

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

BTTX Stock Price History

BTTX Stock News Headlines

Better Therapeutics (BTTX) Set to Announce Earnings on Thursday
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Dow Dips Over 100 Points; Dick's Sporting Goods Earnings Top Views
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
CAH Feb 2024 107.000 put
Biora Therapeutics Provides Outlook for 2024
See More Headlines
Receive BTTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:BTTX
Fax
N/A
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$9.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+42,757.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-39,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.04) per share

Miscellaneous

Free Float
24,233,000
Market Cap
$698,040.00
Optionable
Optionable
Beta
2.35
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. David P. Perry M.B.A. (Age 56)
    Co-Founder & Executive Chairman
    Comp: $260k
  • Mr. Frank L. Karbe (Age 56)
    CEO, Interim CFO, President & Director
    Comp: $533.37k
  • Dr. Mark A. Berman M.D. (Age 49)
    Chief Medical Officer
    Comp: $573.75k
  • Ms. Kristin Wynholds (Age 52)
    Chief Product Officer
    Comp: $519.07k
  • Mr. Andres Camacho
    Senior VP of Technology & Head of Engineering
  • Ms. Angela Willis
    Senior Vice President of Market Access
  • Ms. Jessica Meng
    Chief Commercial Officer
  • Leslie Miller
    Controller

BTTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Better Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BTTX shares.
View BTTX analyst ratings
or view top-rated stocks.

What is Better Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 12-month price targets for Better Therapeutics' shares. Their BTTX share price targets range from $3.00 to $9.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 42,757.1% from the stock's current price.
View analysts price targets for BTTX
or view top-rated stocks among Wall Street analysts.

How have BTTX shares performed in 2024?

Better Therapeutics' stock was trading at $0.1950 at the start of the year. Since then, BTTX shares have decreased by 92.8% and is now trading at $0.0140.
View the best growth stocks for 2024 here
.

Are investors shorting Better Therapeutics?

Better Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,560,000 shares, an increase of 20.2% from the February 29th total of 2,130,000 shares. Based on an average trading volume of 6,410,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 8.3% of the company's stock are sold short.
View Better Therapeutics' Short Interest
.

When is Better Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our BTTX earnings forecast
.

Who are Better Therapeutics' major shareholders?

Better Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include MMCAP International Inc. SPC (0.71%), Vanguard Group Inc. (0.40%), Vanguard Group Inc. (0.40%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew J Armanino, David P Perry, Elder Granger, Frank Karbe, Geoffrey M Parker, Kevin J Appelbaum, Mark A Berman, Mark Heinen and Risa J Lavizzo-Mourey.
View institutional ownership trends
.

How do I buy shares of Better Therapeutics?

Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners